EcoDrugPlus

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSDCDG00000019924
Gene Symbol: TEK
3 Cross references
166 Possible Orthologues:

Tgf-Beta Receptor Type-1

Ensembl ID : ENSDCDG00000033653
Gene Symbol: LOC114778036
3 Cross references
208 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSDCDG00000016376
Gene Symbol: LOC114787983
3 Cross references
161 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSDCDG00000029353
Gene Symbol: TTK
3 Cross references
205 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSDCDG00000014508
Gene Symbol: UGCG
3 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSDCDG00000033912
Gene Symbol: WEE1
3 Cross references
206 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSDCDG00000004625
Gene Symbol: ACHE
3 Cross references
234 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSDCDG00000029001
Gene Symbol: ACVR2B
3 Cross references
196 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSDCDG00000017902
Gene Symbol: ACVR2B
3 Cross references
194 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSDCDG00000026810
Gene Symbol: ADORA1
1 Cross references
208 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSDCDG00000023384
Gene Symbol: ADORA2A
3 Cross references
200 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSDCDG00000022536
Gene Symbol: ADORA2A
3 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).